Intra-Cellular Therapies Inc (ITCI)
68.47
-2.51
(-3.54%)
USD |
NASDAQ |
Jun 28, 16:00
68.47
0.00 (0.00%)
After-Hours: 19:38
Intra-Cellular Therapies Gross Profit (TTM): 475.39M for March 31, 2024
Gross Profit (TTM) Chart
Historical Gross Profit (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 475.39M |
December 31, 2023 | 428.43M |
September 30, 2023 | 388.27M |
June 30, 2023 | 337.61M |
March 31, 2023 | 285.07M |
December 31, 2022 | 228.69M |
September 30, 2022 | 171.02M |
June 30, 2022 | 124.61M |
March 31, 2022 | 91.15M |
Date | Value |
---|---|
December 31, 2021 | 73.67M |
September 30, 2021 | 61.96M |
June 30, 2021 | 49.17M |
March 31, 2021 | 33.95M |
December 31, 2020 | 20.64M |
September 30, 2020 | 9.373M |
June 30, 2020 | 2.561M |
March 31, 2020 | 0.8132M |
December 31, 2019 | 0.00 |
Gross Profit Definition
Gross profit is the difference between sales and the cost of goods sold. Revenues (aka Sales) less Cost of Goods Sold (COGS) is a company's gross profit. For many companies, cost of goods sold is a substantial portion of expenses.
Gross Profit (TTM) Range, Past 5 Years
--
Minimum
Dec 2019
475.39M
Maximum
Mar 2024
154.58M
Average
82.41M
Median
Gross Profit (TTM) Benchmarks
Amgen Inc | 19.60B |
Johnson & Johnson | 61.53B |
Eli Lilly and Co | 28.80B |
Madrigal Pharmaceuticals Inc | -- |
Viking Therapeutics Inc | -- |